Lantern Pharma Inc - Company Profile
Powered by 
All the sales intelligence you need on Lantern Pharma Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Lantern Pharma Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Lantern Pharma Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Lantern Pharma Inc (Lantern Pharma) is a clinical-stage pharmaceutical company. It leverages artificial intelligence, genomics, and machine learning to accelerate the discovery and development of precision oncology therapies. Its pipeline products include LP-300, for non-small cell lung cancer; LP-184, for advanced solid tumors; LP-284, for non-hodgkin's lymphomas; ADC, for solid tumors. Its other pipelines include elraglusib, TTC-352, XCE853, ADC, and STAR-001, for adult CNS cancers and pediatric CNS cancers. Lantern Pharma's products are designed for cancer patients, with applications in personalized medicine to improve treatment outcomes. It operates in the UK, the US and Australia. Lantern Pharma is headquartered in Dallas, Texas, the UK.
Headquarters
United States of America
Address
1920 Mckinney Avenue, 7th Floor, Dallas, Texas, 75201
Website
www.lanternpharma.com
Telephone
1 972 2771136
No of Employees
16
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
LTRN (NASD)
EPS
XYZ
Net Income (2024)
XYZ
17.6%
(2024 vs 2023)
Market Cap*
$39.6M
* As of and is in US$
Lantern Pharma Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| LP-300: Non-Small Cell Lung Cancer (NSCLC) |
| LP-184: |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Contracts/Agreements | In January, the company announced a collaboration and research agreement with The Danish Cancer Society Research Center to examine the clinical development of drug candidates, LP-100 and LP-184, in solid tumors. |
| 2021 | Contracts/Agreements | In September, the company and Deep Lens entered into a strategic collaboration to leverage Deep Lens' artificial intelligence clinical trial matching solution, VIPERO. |
| 2021 | Regulatory Approval | In August, the company secured a FDA approval for its LP-184 for the treatment of pancreatic cancer. |
Competitor Comparison
| Key Parameters | Lantern Pharma Inc | Puma Biotechnology Inc | Precision Biosciences Inc | Actinium Pharmaceuticals Inc | Qsam Biosciences Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Dallas | Los Angeles | Durham | New York City | Austin |
| State/Province | Texas | California | North Carolina | New York | Texas |
| No. of Employees | 16 | 179 | 68 | 25 | 4 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Panna Sharma | Chief Executive Officer; Director; President | Executive Board | 2024 | 54 |
| David R. Margrave | Chief Financial Officer; Secretary | Senior Management | 2024 | 65 |
| Kishor G. Bhatia | Chief Scientific Officer | Senior Management | 2019 | 70 |
| Marc Chamberlain | Chief Medical Officer - Starlight Therapeutics | Senior Management | 2024 | - |
| Reggie Ewesuedo | Vice President - Clinical Development | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer